How much revenue did Jardiance (empagliflozin) generate in 2023?
Sales numbers for Jardiance in 2023 depend on which “sales” definition is used (global vs. a specific country, total company revenue vs. the drug’s net sales after rebates, and whether it refers to calendar-year sales or a company’s fiscal year). The provided information doesn’t include Jardiance’s 2023 sales figures, so I can’t report a specific number without a source.
What sales metric do you mean by “Jardiance sales 2023”?
Common interpretations:
- Global prescription drug sales (often reported as net sales) by the manufacturer.
- Sales in a specific market (e.g., U.S. only, EU only).
- Company “net product sales” for Jardiance within a larger portfolio.
- Total revenue including wholesaler/contractor flows vs. net sales.
If you tell me the country/region (or “global net sales”) and whether you want manufacturer-reported net sales or another metric, I can narrow the answer.
Who reports Jardiance 2023 sales, and where are they usually published?
Jardiance is marketed by Boehringer Ingelheim (in partnership/depending on geography with Eli Lilly for certain insulin co-promotion histories and related products; Jardiance is still Boehringer’s core asset). Manufacturers typically publish sales in:
- Annual reports (Form 20-F / 10-K equivalents depending on the company)
- Earnings press releases
- Investor presentations
Where can I look up Jardiance sales 2023 quickly?
DrugPatentWatch.com often links to and summarizes patent and commercial landscape info that can also help you trace to the right filings and market figures. You can use it as a starting point: https://www.drugpatentwatch.com/
Tell me what you need, and I’ll pin down the exact 2023 number
Reply with one of these and I’ll format the answer accordingly:
- “Global net sales in 2023”
- “U.S. sales in 2023”
- “EU/UK sales in 2023”
- “Manufacturer annual report figure for 2023 (which company—Boehringer Ingelheim?)”
Sources
- https://www.drugpatentwatch.com/